Literature DB >> 7850918

Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.

P F Lenehan1, P L Gutiérrez, J L Wagner, N Milak, G R Fisher, D D Ross.   

Abstract

PURPOSE: It has been recognized that enhanced antioxidant defenses can contribute to the resistance of cancer cells displaying multidrug resistance (MDR) that arises in conjunction with the overexpression of P-glycoprotein (Pgp). The purpose of this study was to determine if the defenses against oxidant stress in MDR human leukemia cells (HL-60/AR) that overexpress multidrug-resistance-associated protein (MRP), but not Pgp, contribute to the mechanism of drug resistance in this cell line.
METHODS: HL-60/AR cells were evaluated in comparison with wild-type cells with respect to sensitivity to the oxidants hydrogen peroxide (H2O2) and tert-butyl hydroperoxide (t-BuOOH), the activities and amounts of the antioxidant enzymes catalase and glutathione peroxidase (GSH-Px), and the effects that manipulation of the activities of these enzymes may have on cellular sensitivity to the oxidants and to daunorubicin. We also evaluated the ability of the cells to generate daunorubicin semiquinone free radical as measured by electron spin resonance (ESR) spectroscopy.
RESULTS: HL-60/AR cells were > 10-fold resistant to the cytotoxic effects of the H2O2 or t-BuOOH as compared with parental, drug-sensitive HL-60 cells. This phenomenon could be attributed largely to elevated activity and protein levels of catalase in HL-60/AR cells. Furthermore, inhibition of catalase by 3-amino-1,2,4-triazole (AT) diminished the resistance of HL-60/AR to these oxidants by > 80% or > 50%, respectively. Despite these findings, AT was incapable of causing sensitization of HL-60/AR cells to the cytotoxic effects of daunorubicin. We found that the activity and amount of selenium-dependent glutathione peroxidase (GSH-Px) was no greater in HL-60/AR cells than in HL-60 cells. Cultivation of cells in selenium-deficient medium caused a marked reduction in GSH-Px activity in HL-60/AR cells and a profound inhibition of GSH-redox cycling manifested by a decrease in baseline hexose monophosphate shunt activity (HMPS) and markedly blunted stimulation of the HMPS by the oxidant t-BuOOH in both wild-type and resistant cells. These variations in GSH-Px activity and GSH-redox cycling, however, were not associated with an alteration in cellular sensitivity to daunorubicin. The failure of catalase inhibition or selenium manipulation of GSH-Px activity to affect daunorubicin cytotoxicity was not due to the inability of these cells to produce free-radical species of daunorubicin, since ESR studies revealed that the generation of daunorubicin semiquinone free radical by HL-60/AR cells was equal to and, in fact, 3-fold that obtained with HL-60 cells.
CONCLUSIONS: In comparison with parental HL-60 cells, MRP-overexpressing HL-60/AR cells have demonstrable alterations in antioxidant defenses that are manifested by cellular resistance to the cytotoxic effects of H2O2 and t-BuOOH and by elevated protein levels and activity of catalase. Whether these alterations are epiphenomena or are related to overexpression of MRP remains to be determined. However, it does appear that the enhanced antioxidant defenses observed in HL-60/AR cells do not contribute to the resistance to daunorubicin manifested by this cell line. Although HL-60/AR cells generate daunorubicin semiquinone free radical to an extent equal to or greater than that observed in HL-60 cells, the failure of alterations in GSH-Px activity or inhibition of catalase to change the sensitivity of HL-60/AR cells to daunorubicin suggests that the cytotoxicity of daunorubicin in these cells in not mediated through H2O2 or other peroxide species detoxified by these enzymes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7850918     DOI: 10.1007/s002800050250

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  40 in total

1.  In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.

Authors:  P L Gutierrez; P J Wilder; N Biswal
Journal:  Cancer Commun       Date:  1989

2.  Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number.

Authors:  D D Ross; C C Joneckis; J V Ordóñez; A M Sisk; R K Wu; R E Hamburger AW Nora; R E Nora
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

3.  Differential oxygen radical susceptibility of adriamycin-sensitive and -resistant MCF-7 human breast tumor cells.

Authors:  E G Mimnaugh; L Dusre; J Atwell; C E Myers
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

4.  Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells.

Authors:  J Lutzky; M B Astor; R N Taub; M A Baker; K Bhalla; J E Gervasoni; M Rosado; V Stewart; S Krishna; A A Hindenburg
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

5.  The reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells: free radical formation and NAD(P)H: quinone-acceptor oxidoreductase (DT-diaphorase) activity.

Authors:  G R Fisher; P L Gutierrez
Journal:  Free Radic Biol Med       Date:  1991       Impact factor: 7.376

6.  Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein.

Authors:  T McGrath; M S Center
Journal:  Biochem Biophys Res Commun       Date:  1987-06-30       Impact factor: 3.575

7.  Cellular activation of diaziquone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone] to its free radical species.

Authors:  P L Gutierrez; M J Egorin; B M Fox; R Friedman; N R Bachur
Journal:  Biochem Pharmacol       Date:  1985-05-01       Impact factor: 5.858

8.  Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity.

Authors:  P L Gutiérrez; M V Gee; N R Bachur
Journal:  Arch Biochem Biophys       Date:  1983-05       Impact factor: 4.013

9.  Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.

Authors:  D D Ross; P J Wooten; R Sridhara; J V Ordóñez; E J Lee; C A Schiffer
Journal:  Blood       Date:  1993-08-15       Impact factor: 22.113

10.  Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein.

Authors:  D Marquardt; S McCrone; M S Center
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

View more
  8 in total

1.  Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy.

Authors:  Subash C Gupta; David Hevia; Sridevi Patchva; Byoungduck Park; Wonil Koh; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2012-01-16       Impact factor: 8.401

Review 2.  Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer.

Authors:  Luksana Chaiswing; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2018-02-21       Impact factor: 8.401

3.  Intracellular catalase activity instead of glutathione level dominates the resistance of cells to reactive oxygen species.

Authors:  Meng-Xin Zhao; Jun-Lin Wen; Lu Wang; Xiao-Ping Wang; Tong-Sheng Chen
Journal:  Cell Stress Chaperones       Date:  2019-04-15       Impact factor: 3.667

Review 4.  Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds.

Authors:  Gang Chen; Feng Wang; Dunyaporn Trachootham; Peng Huang
Journal:  Mitochondrion       Date:  2010-08-14       Impact factor: 4.160

5.  Resistance to thapsigargin-induced intracellular calcium mobilization in a multidrug resistant tumour cell line.

Authors:  Karen Wagner-Souza; Juliana Echevarria-Lima; Louise A P Rodrigues; Marcelo Reis; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 6.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Authors:  Dunyaporn Trachootham; Jerome Alexandre; Peng Huang
Journal:  Nat Rev Drug Discov       Date:  2009-05-29       Impact factor: 84.694

7.  Inhibition of catalase by tea catechins in free and cellular state: a biophysical approach.

Authors:  Sandip Pal; Subrata Kumar Dey; Chabita Saha
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

Review 8.  Cancer drug resistance: redox resetting renders a way.

Authors:  Yuan Liu; Qifu Li; Li Zhou; Na Xie; Edouard C Nice; Haiyuan Zhang; Canhua Huang; Yunlong Lei
Journal:  Oncotarget       Date:  2016-07-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.